New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively)1 A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm […]

Related Keywords

United States ,South Korea ,Switzerland ,China ,Netherlands ,Amsterdam ,Noord Holland ,Japan ,America ,American ,Swiss ,Han ,Michael Meo ,Marlena Abdinoor ,Michael Koren ,Parag Mahanti ,Jonathan Graham ,Sloan Simpson ,Coll Cardiol ,Health Promotion Series ,Alnylam Pharmaceuticals ,American Heart Association ,European Medicines Agency ,Novartis Pharmaceuticals Corp ,American College Of Cardiology Congress ,American College Of Cardiology Heart Association ,National Medical Products Administration ,World Heart Federation ,Clinical Research ,Journal Of The American College Cardiology ,Instagram ,Novartis ,European Union ,Exchange Commission ,Facebook ,European Society Of Cardiology Congress ,Linkedin ,Novartis Pharmaceuticals Corporation ,World Health Organization ,Jacksonville Center ,Public Health ,Annual Scientific Session ,American College ,Medical Director ,Safety Information ,Atherosclerotic Cardiovascular Disease ,Cardiology Congress ,European Society ,Medical Products ,American Heart ,American Heart Association Task Force ,Clinical Practice ,World Heart ,Published May ,